- I. To prospectively determine the sensitivity and specificity of dynamic susceptibility
contrast (DSC)-MRI parameters in detecting tumor recurrence versus radiation necrosis for
brain metastases treated with stereotactic radiosurgery (SRS).
- I. To correlate radiographic diagnoses with pathologic diagnoses when surgical resection is
- II. To correlate baseline relative cerebral blood volume (rCBV) values and other hemodynamic
parameters with tumor primary histology.
- III. To assess overall survival, local failure, distant brain failure and neurologic death.
Participants undergo a diagnostic MRI with and without contrast and treatment planning DSC
perfusion MRI series before receiving SRS at 4-6 weeks after SRS, and then every 3 months
unless clinically indicated sooner.